Diabetes drug tested as potential Alzheimer's treatment
NCT ID NCT05891496
Summary
This study tested whether semaglutide, a medication used for diabetes and weight loss, could help control Alzheimer's disease by reducing brain inflammation. Twenty-three people with mild Alzheimer's symptoms received either the drug or a placebo for 12 weeks, followed by the drug for everyone for another year. Researchers measured changes in brain and blood cells to see if the drug affected the immune system's role in the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera Spedali Civili di Brescia
Brescia, 25123, Italy
-
Azienda Ospedaliera di Perugia;Ospedale S. Maria della Miser
Perugia, 06132, Italy
-
Banner Sun Health Research Institute
Sun City, Arizona, 85351, United States
-
Brain Matters Research
Delray Beach, Florida, 33445, United States
-
Centre de la Mémoire
Geneva, 1205, Switzerland
-
Fondazione Santa Lucia IRCCS
Roma, 00179, Italy
-
Karolinska Universitetssjukhuset, Huddinge
Stockholm, 141 86, Sweden
-
Memory Program
Toronto, Ontario, M3B2S7, Canada
-
Ottawa Memory Clinic
Ottawa, Ontario, K1Z 1G3, Canada
-
Rigshospitalet - afsnit 8015
København Ø, 2100, Denmark
-
Rigshospitalet - afsnit 8015 Hukommelsesklinikken
København Ø, 2100, Denmark
Conditions
Explore the condition pages connected to this study.